NRx Pharmaceuticals (NASDAQ:NRXP) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of NRx Pharmaceuticals (NASDAQ:NRXP) from a hold rating to a sell rating in a research note released on Saturday morning.

NRXP has been the topic of a number of other reports. D. Boral Capital reaffirmed a “buy” rating and set a $34.00 target price on shares of NRx Pharmaceuticals in a report on Monday, November 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research report on Wednesday, October 8th. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of NRx Pharmaceuticals in a report on Thursday, October 16th. Zacks Research raised shares of NRx Pharmaceuticals to a “hold” rating in a research note on Wednesday, September 10th. Finally, Ascendiant Capital Markets lifted their price objective on shares of NRx Pharmaceuticals from $46.00 to $47.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $34.75.

NRx Pharmaceuticals Stock Down 3.9%

Shares of NASDAQ NRXP opened at $2.49 on Friday. NRx Pharmaceuticals has a fifty-two week low of $1.13 and a fifty-two week high of $6.01. The firm’s 50-day simple moving average is $3.02 and its 200 day simple moving average is $2.88. The stock has a market cap of $49.33 million, a P/E ratio of -1.06 and a beta of 1.76.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its earnings results on Friday, November 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.07). The company had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $6.83 million. On average, sell-side analysts anticipate that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NRx Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Two Sigma Investments LP increased its stake in shares of NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after acquiring an additional 20,880 shares during the last quarter. Vanguard Group Inc. grew its stake in NRx Pharmaceuticals by 18.3% in the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after purchasing an additional 82,781 shares in the last quarter. AdvisorShares Investments LLC increased its position in NRx Pharmaceuticals by 29.7% in the 3rd quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock worth $1,129,000 after purchasing an additional 78,339 shares during the last quarter. One Wealth Management Investment & Advisory Services LLC raised its stake in shares of NRx Pharmaceuticals by 86.1% during the 3rd quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after purchasing an additional 12,950 shares in the last quarter. Finally, Ethos Financial Group LLC acquired a new stake in shares of NRx Pharmaceuticals during the 3rd quarter valued at about $39,000. Institutional investors and hedge funds own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.